StockData
INSMED Inc logo

INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3099% above fair value
$119.80−2.06 (-1.69%)

Close on Nov 18, 2026Market cap $26.28BP/E –Yield –

Insmed revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Insmed's revenue for the twelve months ending Sep 30, 2026 was $1.52B, up 240.0% year over year. For fiscal 2025 it was $606.42M, up 66.7% from the year before. The highest annual figure on record is $606.42M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$606.42M+66.7%
FY2024Dec 31, 2024$363.71M+19.2%
FY2023Dec 31, 2023$305.21M+24.4%
FY2022Dec 31, 2022$245.36M+30.2%
FY2021Dec 31, 2021$188.46M+14.6%
FY2020Dec 31, 2020$164.41M+20.5%
FY2019Dec 31, 2019$136.47M+1287.6%
FY2018Dec 31, 2018$9.84M–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–
FY2015Dec 31, 2015$0-100.0%
FY2013Dec 31, 2013$11.50M–
FY2012Dec 31, 2012$0-100.0%
FY2011Dec 31, 2011$4.42M-36.2%
FY2010Dec 31, 2010$6.92M-33.3%
FY2009Dec 31, 2009$10.37M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$524.43M+268.4%
Q2 FY2026Jun 30, 2026$425.49M+296.1%
Q1 FY2026Mar 31, 2026$305.96M+229.6%
Q4 FY2025Dec 31, 2025$263.84M+152.6%
Q3 FY2025Sep 30, 2025$142.34M+52.4%
Q2 FY2025Jun 30, 2025$107.42M+18.9%
Q1 FY2025Mar 31, 2025$92.82M+22.9%
Q4 FY2024Dec 31, 2024$104.44M+24.8%
Q3 FY2024Sep 30, 2024$93.43M+18.2%
Q2 FY2024Jun 30, 2024$90.34M+17.0%
Q1 FY2024Mar 31, 2024$75.50M+15.8%
Q4 FY2023Dec 31, 2023$83.69M+41.1%
Q3 FY2023Sep 30, 2023$79.07M+16.7%
Q2 FY2023Jun 30, 2023$77.23M+18.4%
Q1 FY2023Mar 31, 2023$65.21M+22.8%
Q4 FY2022Dec 31, 2022$59.30M+5.7%
Q3 FY2022Sep 30, 2022$67.73M+44.9%
Q2 FY2022Jun 30, 2022$65.22M+43.8%
Q1 FY2022Mar 31, 2022$53.11M+32.1%
Q4 FY2021Dec 31, 2021$56.12M+35.5%
Q3 FY2021Sep 30, 2021$46.76M+7.1%
Q2 FY2021Jun 30, 2021$45.37M+6.8%
Q1 FY2021Mar 31, 2021$40.21M+9.1%
Q4 FY2020Dec 31, 2020$41.42M-9.4%
Q3 FY2020Sep 30, 2020$43.64M+12.2%
Q2 FY2020Jun 30, 2020$42.50M+41.8%
Q1 FY2020Mar 31, 2020$36.86M+68.3%
Q4 FY2019Dec 31, 2019$45.71M+364.7%
Q3 FY2019Sep 30, 2019$38.89M–
Q2 FY2019Jun 30, 2019$29.97M–
Q1 FY2019Mar 31, 2019$21.90M–
Q4 FY2018Dec 31, 2018$9.84M–
Q3 FY2018Sep 30, 2018$0–
Q2 FY2018Jun 30, 2018$0–
Q1 FY2018Mar 31, 2018$0–
Q4 FY2017Dec 31, 2017$0–
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$0–

More Insmed figures

See a number that looks wrong?